Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1450 results about "Cell adhesion" patented technology

Cell adhesion is the process by which cells interact and attach to neighbouring cells through specialised molecules of the cell surface. This process can occur either through direct contact between cell surfaces or indirect interaction, where cells attach to surrounding extracellular matrix, a gel-like structure containing molecules released by cells into spaces between them. Cells adhesion occurs from the interactions between cell-adhesion molecules (CAMs), transmembrane proteins located on the cell surface. Cell adhesion links cells in different ways and can be involved in signal transduction for cells to detect and respond to changes in the surroundings. Other cellular processes regulated by cell adhesion include cell migration and tissue development in multicellular organisms. Alterations in cell adhesion can disrupt important cellular processes and lead to a variety of diseases, including cancer and arthritis. Cell adhesion is also essential for infectious organisms, such as bacteria or viruses, to cause diseases.

Bioabsorbable wound dressing

A wound dressing includes a first layer located adjacent the wound and which comprises a material that is bioabsorbable, porous and adapted for serving as a scaffold for cell attachment and proliferation; and a second layer which is in contact with the first layer and which comprises an absorbent, gel forming material adapted for serving as a barrier to cell adhesion and penetration. A method of treating a wound with the dressing is also disclosed.
Owner:AVENT INC

Humanized anti-CD11a antibodies

Humanized anti-CD11a antibodies and various uses therefor are disclosed. The humanized anti-CD11a antibody may bind specifically to human CD11a I-domain, have an IC50(nM) value of no more than about 1 nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1, and / or an IC50 (nM) value of no more than about 1 nM in the mixed lymphocyte response assay.
Owner:GENENTECH INC

Placental tissue grafts and improved methods of preparing and using the same

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.
Owner:MIMEDX GROUP

Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation

This invention relates to a method of inhibiting tumor cell adhesion, pain, and inflammation at a wound during a surgical procedure by delivering an irrigation solution containing a tumor cell anti-adhesion agent and a plurality of additional agents to an operative site during the surgical procedure. In addition, methods of inhibiting tumor cell attachment and implantation during a surgical procedure as well as inhibiting tumor metastasis during a surgical procedure are also provided.
Owner:OMEROS CORP

Method for creating a cell growth surface on a polymeric substrate

A method, apparatus and product for producing an advantaged cell growth surface. According to the present invention, a stream of plasma is comprised of activated gaseous species generated by a microwave source. This stream is directed at the surface of a polymer substrate in a controlled fashion such that the surface is imparted with attributes for cell adhesion far superior to that of untreated polymer or polymer treated by other known methods.
Owner:CORNING INC

Glaucoma shunts with flow management and improved surgical performance

ActiveUS20100249691A1Improving glaucoma shuntReduce postoperative complicationsEye surgeryIntravenous devicesGlaucoma tube shuntGlaucoma
A method of treating glaucoma in an eye by managing fluid flow past an implanted shunt having an elastomeric plate and a non-valved elastomeric drainage tube. The plate is positioned over a sclera of the eye with an outflow end of the elastomeric drainage tube open to an outer face of the plate. An inflow end of the drainage tube tunnels through the sclera to the anterior chamber of the eye. The plate may have regions of greater propensity for cell adhesion alternating with regions of lesser cell adhesion. For example, regions of texturing around the plate or drainage tube may be provided to control the size of a bleb that forms over the implant. The effective surface area of the plate may be balanced against a number of fenestrations. The drainage tube has a reduced profile and may be shaped with a non-circular external cross-section to reduce its height. A scleral groove may be used to further reduce the height of the drainage tube on the sclera. A flow restrictor for the early post operative period will immediately lower the intraocular pressure (IOP) and simultanously prevent hypotony.
Owner:JOHNSON & JOHNSON SURGICAL VISION INC

Artificial corneal implant

A material that can be applied as implants designed to artificially replace or augment the cornea, such as an artificial cornea, corneal onlay, or corneal inlay (intrastromal lens) is provided. The artificial corneal implant has a double network hydrogel with a first network interpenetrated with a second network. The first network and the second network are based on biocompatible polymers. At least one of the network polymers is based on a hydrophilic polymer. The artificial cornea or implant has epithelialization promoting biomolecules that are covalently linked to the surface of the double network hydrogel using an azide-active-ester chemical linker. Corneal epithelial cells or cornea-derived cells are adhered to the biomolecules. The double network has a physiologic diffusion coefficient to allow passage of nutrients to the adhered cells.
Owner:SANTA CLARA UNIVERSITY

Multilayer device for tissue engineering

The invention provides for translating two-dimensional microfabrication technology into the third dimension. Two-dimensional templates are fabricated using high-resolution molding processes. These templates are then bonded to form three-dimensional scaffold structures with closed lumens. The scaffolds can serve as the template for cell adhesion and growth by cells that are added to the scaffolds through the vessels, holes or pores. These scaffolds can be formed by layering techniques, to interconnect flat template sheets to build up a fully vascularized organ.
Owner:CHARLES STARK DRAPER LABORATORY

Antibody complexes

This invention is directed to a soluble complex of ligands that binds to surface molecules of hemopoietic cells and result in their activation or expansion. The complex may be used in the activation and / or expansion of hemopoietic cells, optionally in combination with their transduction. The complex of ligands bind at least two cell surface molecules, such as one that plays a role in cell-cell adhesion and one that may or may not activate or stimulate the cell to promote growth and / or proliferation after binding to a ligand. A complex of ligands that bind two hemopoietic cell stimulatory molecules is also provided. The invention further provides for the use of the complex to target vectors to hemopoietic cells.
Owner:VIRXSYS

Peptides for enhanced cell attachment and growth

InactiveUS7157275B2Promotes attachment and growth and differentiation and further functionConnective tissue peptidesAdditive manufacturing apparatusCell adhesionAdhesion process
The present invention relates to cell adhesion promoting (“CAP”) peptide combinations that promote cell attachment or cell adhesion to culture surfaces that are otherwise cell adhesion resistant “CAR”. The invention provides combination of peptides that, when covalently coupled to a CAR layer such as hyaluronic acid that has been created on a polystyrene surface, promote cell attachment, growth differentiation, and execution of other desired cellular functions in culture.
Owner:BECTON DICKINSON & CO

Cell growth surface on a polymeric substrate

A product exhibiting an improved cell growth surface and cell attachment. According to the present invention, a stream of plasma is comprised of activated gaseous species generated by a microwave source. This stream is directed at the surface of a polymer substrate in a controlled fashion such that the surface is imparted with attributes for cell adhesion far superior to that of untreated polymer or polymer treated by other methods.
Owner:CORNING INC

Multilayered microcultures

InactiveUS20060141617A1Accurate mimicFlexible and cost-effectiveBioreactor/fermenter combinationsCompound screeningBiological bodyCell adhesion
A multilayer microculture capable of modeling complex in vitro structures such as mammalian tissues and organ structures is provided, along with methods for producing such a microculture and methods of using such microcultures for assaying for modulators of cell-cell interaction, cell migration, cell proliferation, cell adhesion or cellular or organismal physiology. Further provided are methods of identifying hazardous materials such as environmental toxins and pollutants (e.g., carcinogenic compounds), and methods of monitoring organismal physiology.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS

Placental tissue grafts and improved methods of preparing and using the same

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.
Owner:MIMEDX GROUP +1

Biocompatible Coated Nanostructured Titanium Surfaces

Bioactive molecules have been coated on nanotubular structured titanium substrates by molecular plasma deposition. The coatings promote cell adhesion and are particularly suited for orthopedic implants that provide improved bone cell adhesion and new tissue growth. Nanodimensional features on titanium substrates are engineered using electrochemical anodization techniques. The nanostructured surfaces provide superior support for a wide selection of polypeptide coatings.
Owner:METASCAPE

Nucleic acids encoding JTT-1 protein

Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
Owner:JAPAN TOBACCO INC

Blood test prototypes and methods for the detection of circulating tumor and endothelial cells

Methods and devices for isolating and diagnosing disease with a cell adhesion matrix system, mimicking a metastatic, cardiovascular or placental environment, are disclosed. The cell adhesion matrix facilitates the enrichment of target cells such as metastatic tumor cells, fetal cells and endothelial progenitor cells from a fluid sample such as blood for diagnostic and therapeutic applications in treating patients afflicted with disease, such as cancerous, cardiovascular and fetal diseases, as well as for research applications in molecular analysis of metastatic, and cardiovascular and fetal diseases. Blood test prototypes and methods for the cell enrichment and detection of circulating tumor and endothelial cells using multiplex molecular analysis are described herein. In addition, methods and compositions for determining host immunity to tumor in subjects with risk of cancer progression and methods for isolating an enriched fraction of fetal cells from pregnant females for prenatal diagnosis are also described herein.
Owner:CHEN WEN TIEN +2

Surgical adhesive compostion and process for enhanced tissue closure and healing

A surgical tissue adhesive composition contains at least one 1,1-disubstituted electron-deficient olefin macromer. The adhesive composition of the invention has improved biocompatibility as well as controlled biodegradation characteristics and bioactivity. Adhesive co-monomer compositions contain at least one macromer with a pendant oligomer, polymer, or peptide chain as an acrylic ester of the reactive olefin. The polymers formed therefrom have a grafted brush-like nature. The composition is particularly useful for creating an adhesive bond at the junction of living tissue in surgical applications. The adhesive composition may further comprise co-monomer, co-macromer, cross-linker, or inter-penetrating polymer compounds containing peptide sequences that are bioactive or enzyme responsive. The peptide sequences are selected to promote tissue infiltration and healing in a particular biological tissue. The sequences may contain specific cell-adhesion, cell-signaling, and enzyme-cleavable domains. Furthermore, a degradable filler material may be included in the composition to create a reinforced composite. The filler preferably has a higher degradation rate than the polymer matrix, generating porosity upon degradation. The adhesive may further contain entrapped or incorporated drugs or biologics, including antibiotics or growth factors. The adhesive can be used to bind together the edges of living tissues during surgical procedures. The cured composition provides interfacial bonding and mechanical fixation while promoting tissue infiltration and replacement of the adhesive polymer.
Owner:POLLOCK POLYMER GROUP

Sulfated hyaluronic acid and esters thereof

Hyaluronic acid, hyaluronate esters and salts thereof are sulfated such that the number of sulfate groups per monomeric unit is in the range of from 0.5 to 3.5. The sulfated derivatives exhibit anticoagulant and cell adhesion reduction properties, and may be used to prepare biomaterials.
Owner:FIDIA ADVANCED BIOPOLYMERS SRL

Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles

InactiveUS20020068089A1Faster and safe and more comfortable recoveryPowder deliveryBiocideCell adhesionBiocompatibility
The invention encompasses the treatment of urinary incontinence, gastroesophageal reflux disease and the amelioration of skin wrinkles using biocompatible hydrophilic cationic microparticles and a cell adhesion promoter.
Owner:BIOSPHERE MEDICAL INC

Cell-cultivating device

ActiveUS7033823B2Reduces cell injury cellReduces cell even cell mortalityBioreactor/fermenter combinationsBiological substance pretreatmentsBiotechnologyAdhesion process
The present invention claims and discloses a novel apparatus and method for efficiently cultivating cells with minimal mortality in order to harvest a maximum amount of cellular products generated by the cultivated cells. More particularly, the present invention teaches a method and a device for plating cells and causing maximum adherence of cells of interest. Furthermore, the present invention also teaches a growth substrate means that is capable of providing the largest surface area for cell adhesion and functions as an oxygenator, a depth filter and a static mixer to maximize the production of cellular products by intermittently and periodically provide sufficient oxygen and nutrients to the cells without causing cell death. The device of the present invention is economical and can be disposable thus eliminating complications caused by sterlization and is capable of periodically and intermittently provide oxygen and nutrients to cells, through controlling the amount of culture medium that comes into contact with the growth substrate means.
Owner:CESCO BIOENGINEERING CO LTD

Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces

The present invention is directed to a composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces and hydrophobic coated surfaces. The composition is a biomolecule conjugated end-group activated polymer (FGAP). The biomolecule conjugated EGAP can be put to numerous uses including cell adhesion, cell growth, cell sorting, and other biological assays.
Owner:UNIV OF UTAH RES FOUND

Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation

The present invention relates generally to medical devices containing nanoporous surfaces and methods for making same. More specifically, the invention relates to implantable vascular stents or other biomedical devices having at least one nanoporous layer that promotes improved cellular adhesion properties that promote healing and long term biocompatibility. In the case of stents, the nanoporous layer promotes re-endothelialization at sites of stent implantation vasculature, improves overall healing, and reduces inflammation and intimal disease progression. The nanoporous layer may be optionally loaded with one or more therapeutic agent to further improve the function of the implanted stent and further augment clinical efficacy.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND

Modified chitosan having catechol group and biomedical material prepared from modified chitosan

The invention discloses a biomedical material and a product thereof. The biomedical material has main characteristic that a compound having a catechol group structure is grafted on chitosan to form a chitosan biomedical material having the catechol group structure; or the grafted chitosan is cross-linked to prepare a novel macromolecular biomedical material. The catechol has cell adhesion, so that tissue adhesiveness of the chitosan can be changed, and blood cells can be adsorbed on the material surface to achieve better bleeding-steeping effect. By virtue of the mediation, performance of the chitosan is improved, and tissue affinity is improved. The material is prepared into a novel bleeding-stopping sponge by freeze-drying, and prepared into novel dressing by spinning or prepared into powder dressing by reverse flocculating.
Owner:HAINAN JIANKE PHARMA

Macromolecule thiolated modified derivatives and cross-linking material thereof

The present invention discloses a macromolecular sulfydryl modified derivative with general formula (I) or (II) as well as corresponding dithio-bond cross-linking material and corresponding cross-linking material of sulfydryl reaction active cross linker. Wherein, R1 and R2 include alkylidene, substituted alkylidene, aromatic base, polyether polyols, etc. and R1 and R2 can have the same or different chemical structure; P refers to macromolecular compound residue including carboxyl in the side chain and the molecular weight of the macromolecular sulfydryl modified derivative is 10 to 5 million. The side-chain chemical structure of the macromolecular sulfydryl modified derivative with general formula (I) or (II) is flexible and changeable with notable advantages of adjustable performance, mild preparation conditions, high production rate, high modification and controllability. The cross-linking material of the macromolecular sulfydryl modified derivative provided by the present invention can be used to inhibit the attachment of cells and used as the matrix for cell adhesion and growth.
Owner:BIOREGEN BIOMEDICAL (CHANGZHOU) CO LTD

Bone graft and scaffolding materials immobilized with osteogenesis enhancing peptides on the surface

The present invention relates to a bone graft material and a scaffold for tissue engineering applications, which have an osteogenesis-promoting peptide immobilized on the surface. More particularly, the invention relates to a bone graft material and a scaffold for tissue engineering applications, which have a cell adhesion-inducing peptide and / or tissue growth factor-derived peptide immobilized on the surface. By the osteogenesis-promoting peptide immobilized on the surface, the inventive bone graft material and scaffold for tissue engineering applications can promote the transition, proliferation and differentiation of cells associated with regeneration, and eventually maximize the regeneration of tissue. Moreover, the peptide immobilized on the surface has low molecular weight, indicating a reduced risk of immune responses upon its application in the body, and can be present in a stable form within the body, thus showing lasting effects. Accordingly, the peptide makes it expedient to perform surgical operations for the regeneration of periodontal tissue, alveolar bone and other bone tissues, and will show high therapeutic effect.
Owner:SEOUL NAT UNIV R&DB FOUND

Method of isolating epithelial cells, method of preconditioning cells, and methods of preparing bioartificial skin and dermis with the epithelial cells or the preconditioned cells

A method of isolating epithelial cells from a human skin tissue or internal organ tissue using trypsin and ethylenediamine tetraacetic acid (EDTA) simultaneously with the application of magnetic stirring, a method of preconditioning isolated biological cells by the application of physical stimulus, i.e., strain, are provided. Epithelial cells can be isolated by the method with increased yield, colony forming efficiency (CFE), and colony size. Also, the increased percentage of stem cells in isolated cells is advantageous in therapeutic tissue implantation by autologous or allogeneic transplantation. In skin cells preconditioned by the application of strain, cell division is facilitated, and the secretion of extracellular matrix components and growth factors and the activity of matrix metalloproteinases (MMPs) are improved. When preconditioned cells are implanted by autologous or allogeneic transplantation to heal a damaged tissue, the improved cell adhesion, mobility, and viability provides a biological adjustment effect against a variety of stresses or physical stimuli which the cells would undergo after implantation, with improved capability of integration into host tissue, thereby markedly improving the probability of success in skin grafting.
Owner:KOREA INST OF RADIOLOGICAL & MEDICAL SCI

Method of making cell growth surface

The present invention discloses a three-dimensional porous growth surface made from polysaccharide material, especially the alginic acid, to enhance cell growth surface, promote cell adherence, immobilization and propagation, maintain surface structure integrity, enable programmable degradation, and thus increase cellular production. The present invention teaches several methods: a method to enhance the integrity of the growth surface by protecting the growth surface in a rigid solid support; a method of use for enhancing the performance of the surface; and a method of modifying a growth surface for eukaryotic and / or prokaryotic cells comprising the steps of increasing surface area by creating porous and 3-D structure, treating a surface to encourage cell attachment, promoting cell growth and proliferation, and disposing the growth surface in any conventional cell cultivating device. The growth surface is able to program degradation and release the cell / tissue mass after the culture is completed.
Owner:CESCO BIOENGINEERING CO LTD

Polymer coated nanofibrillar structures and methods for cell maintenance and differentiation

The invention provides cell-adherent polymeric coatings for articles having a nanofibrillar structure. The coatings include a synthetic, non-biodegradable polymer having at least one pendent amine group, wherein the polymer is covalently immobilized on the article via latent reactive groups. The invention also provides methods for the long term culturing of cells using the polymer coated nanofibrillar structures. The polymer coated nanofibrillar structures of the invention have been found to be particularly useful for the growth and differentiation of cells, including neural precursors.
Owner:LODHI MUHAMMAD +4

Dual-functional nonfouling surfaces and materials

Dual-functional nonfouling surfaces and materials, methods for making dual-functional nonfouling surfaces and materials, and devices that include dual-functional nonfouling surfaces and materials. The dual-functional surfaces are nonfouling surfaces that resist non-specific protein adsorption and cell adhesion. The dual-functional surfaces and materials include covalently coupled biomolecules (e.g., target binding partners) that impart specific biological activity thereto. The surfaces and materials are useful in medical diagnostics, biomaterials and bioprocessing, tissue engineering, and drug delivery.
Owner:UNIV OF WASHINGTON

Modified two-component gelation systems, methods of use and methods of manufacture

Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and / or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
Owner:ABBOTT CARDIOVASCULAR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products